A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: BPI-16350|DRUG: placebo|DRUG: Fulvestrant
Sponsor: Betta Pharmaceuticals Co., Ltd.